Skip to main content
. 2016 Nov 3;8(14):23880–23890. doi: 10.18632/oncotarget.13054

Figure 4. Pairwise meta-analysis for the recurrence risk of NMIBC during the follow-up period.

Figure 4

NBI-TUR was associated with a significant benefit in the 3-mo recurrence risk a., 1-yr recurrence risk b. and 2-yr recurrence risk c.